Literature DB >> 22270375

Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome.

A P Goldstone1, A J Holland, J V Butler, J E Whittington.   

Abstract

OBJECTIVE: Prader-Willi syndrome (PWS) is a genetic neurodevelopmental disorder with several nutritional phases during childhood proceeding from poor feeding, through normal eating without and with obesity, to hyperphagia and life-threatening obesity, with variable ages of onset. We investigated whether differences in appetite hormones may explain the development of abnormal eating behaviour in young children with PWS.
SUBJECTS: In this cross-sectional study, children with PWS (n=42) and controls (n=9) aged 7 months-5 years were recruited. Mothers were interviewed regarding eating behaviour, and body mass index (BMI) was calculated. Fasting plasma samples were assayed for insulin, leptin, glucose, peptide YY (PYY), ghrelin and pancreatic polypeptide (PP).
RESULTS: There was no significant relationship between eating behaviour in PWS subjects and the levels of any hormones or insulin resistance, independent of age. Fasting plasma leptin levels were significantly higher (mean ± s.d.: 22.6 ± 12.5 vs 1.97 ± 0.79 ng ml(-1), P=0.005), and PP levels were significantly lower (22.6 ± 12.5 vs 69.8 ± 43.8 pmol l(-1), P<0.001) in the PWS group compared with the controls, and this was independent of age, BMI, insulin resistance or IGF-1 levels. However, there was no significant difference in plasma insulin, insulin resistance or ghrelin levels between groups, though PYY declined more rapidly with age but not BMI in PWS subjects.
CONCLUSION: Even under the age of 5 years, PWS is associated with low levels of anorexigenic PP, as in older children and adults. Hyperghrelinaemia or hypoinsulinaemia was not seen in these young children with PWS. Change in these appetite hormones was not associated with the timing of the transition to the characteristic hyperphagic phase. However, abnormal and/or delayed development or sensitivity of the effector pathways of these appetitive hormones (for example, parasympathetic and central nervous system) may interact with low PP levels, and later hyperghrelinaemia or hypoinsulinaemia, to contribute to hyperphagia in PWS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22270375     DOI: 10.1038/ijo.2011.274

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  20 in total

1.  Obesity in patients with Bardet-Biedl syndrome: influence of appetite-regulating hormones.

Authors:  Anja K Büscher; Metin Cetiner; Rainer Büscher; Anne-Margret Wingen; Berthold P Hauffa; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2012-06-05       Impact factor: 3.714

Review 2.  Review of Prader-Willi syndrome: the endocrine approach.

Authors:  Ryan Heksch; Manmohan Kamboj; Kathryn Anglin; Kathryn Obrynba
Journal:  Transl Pediatr       Date:  2017-10

3.  Exploring genetic susceptibility to obesity through genome functional pathway analysis.

Authors:  Alexander P Gabrielli; Ann M Manzardo; Merlin G Butler
Journal:  Obesity (Silver Spring)       Date:  2017-05-05       Impact factor: 5.002

Review 4.  Update on Diabetes Mellitus and Glucose Metabolism Alterations in Prader-Willi Syndrome.

Authors:  Antonino Crinò; Graziano Grugni
Journal:  Curr Diab Rep       Date:  2020-02-06       Impact factor: 4.810

5.  Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study.

Authors:  Jennifer L Miller; Roy Tamura; Merlin G Butler; Virginia Kimonis; Carlos Sulsona; June-Anne Gold; Daniel J Driscoll
Journal:  Am J Med Genet A       Date:  2017-03-30       Impact factor: 2.802

6.  Hyperghrelinemia in Prader-Willi syndrome begins in early infancy long before the onset of hyperphagia.

Authors:  Frederick A Kweh; Jennifer L Miller; Carlos R Sulsona; Clive Wasserfall; Mark Atkinson; Jonathan J Shuster; Anthony P Goldstone; Daniel J Driscoll
Journal:  Am J Med Genet A       Date:  2014-10-29       Impact factor: 2.802

Review 7.  Prader- Willi syndrome: An uptodate on endocrine and metabolic complications.

Authors:  Giovanna Muscogiuri; Gloria Formoso; Gabriella Pugliese; Rosaria Maddalena Ruggeri; Elisabetta Scarano; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2019-06       Impact factor: 6.514

Review 8.  Ghrelin and eating disorders.

Authors:  Deniz Atalayer; Charlisa Gibson; Alexandra Konopacka; Allan Geliebter
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-08-30       Impact factor: 5.067

Review 9.  Prader Willi Syndrome: Genetics, Metabolomics, Hormonal Function, and New Approaches to Therapy.

Authors:  Krystal A Irizarry; Mark Miller; Michael Freemark; Andrea M Haqq
Journal:  Adv Pediatr       Date:  2016-08

Review 10.  Apo-Ghrelin Receptor (apo-GHSR1a) Regulates Dopamine Signaling in the Brain.

Authors:  Andras Kern; Cristina Grande; Roy G Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2014-08-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.